We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to Janssen, the decision comes despite the consultation papers highlighting the regimen as an innovative treatment combination, which the firm said boosts overall survival and slashes the risk of death by 50 percent.